Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04660630
Other study ID # 2020-1-21-1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 21, 2020
Est. completion date January 20, 2025

Study information

Verified date December 2020
Source Beijing Chao Yang Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness, safety and health economics of precise drug use strategies based on pharmacogenomics compared with traditional drug use strategies for cardiovascular related chronic diseases.


Description:

This study is a randomized controlled, single blind, multicenter clinical study. Beijing Chaoyang Hospital is the team leader, and director Liu Lihong is the project leader. The sub center is Daming County Street Town Health Center and Daming County Jiuzhi township health center. The team leader is responsible for the formulation, implementation and coordination of the research plan, and each sub center is responsible for the implementation of the specific study, patient management and research information feedback. Three project groups were set up in this study: primary hypertension, type 2 diabetes and hyperlipidemia. In each group, the control group and the experimental group were set up, and the patients in two pilot towns of Daming County were selected by cluster stratified random sampling. The control group received the treatment of local researchers according to the traditional medication strategy. The patients in the experimental group were treated with the drug regimen formulated by local researchers according to the results of their pharmacogenomic test reports. The subjects were single blind.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1172
Est. completion date January 20, 2025
Est. primary completion date December 20, 2023
Accepts healthy volunteers No
Gender All
Age group 55 Years to 120 Years
Eligibility Inclusion Criteria: 1. They are 55 years old or above, with no gender restriction. They are permanent residents of Da-jie town and Jiu-zhi Township in Da-ming County. 2. Patients who meet one of the following: A. Hypertension project group: Primary hypertension was definitely diagnosed, systolic blood pressure = 140 millimeter of mercury, diastolic blood pressure = 90 millimeter of mercury, or both after drug treatment. B.Type 2 Diabetes project group: Patients with type 2 diabetes mellitus (non insulin dependent diabetes mellitus) who were diagnosed as type 2 diabetes mellitus (NIDDM) and had HbA1c = 7.0% after drug treatment before enrollment. C.Hyperlipidemia project group: Those who were diagnosed as hyperlipidemia and were treated with or without medication before enrollment. 3. Patients who can provide real and reliable information related to drug treatment and efficacy evaluation Exclusion Criteria: 1. Respondents who are not willing to fill in the true and reliable information form for any reason. 2. Patients with infectious diseases or serious life-threatening diseases such as malignant tumors. 3. Patients with severe liver and kidney function damage, affecting the choice of treatment drugs. 4. Patients with incomplete data related to study evaluation such as any of following: A.The clinical data did not include systolic blood pressure, diastolic blood pressure, heart rate, glycosylated hemoglobin, fasting blood glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride core efficacy evaluation indicators. B.The data related to adverse reactions required by clinical research can not be collected, including but not limited to the related drugs with adverse reactions, adverse reaction performance, time correlation, whether to stop suspicious drugs, and whether to stimulate adverse reactions by re-medication. C.The information of medication compliance score and quality of life score could not be provided for any reason.

Study Design


Intervention

Diagnostic Test:
Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases
According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
Behavioral:
Regular follow-up and patient education
The subjects received regular follow-up and patient education.

Locations

Country Name City State
China Beijng Chao Yang Hospital Beijing

Sponsors (2)

Lead Sponsor Collaborator
Beijing Chao Yang Hospital China development research foundation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Change of the total costs of hypertension treatment Change of annualized cost of hypertension treatment from baseline. 12 months
Other Change of the medicine costs of hypertension treatment Change of annualized cost of hypertension treatment from baseline. 12 months
Other Change of the total costs of diabetes treatment Change of annualized cost of diabetes treatment from baseline. 12 months
Other change of the medicine costs of diabetes treatment Change of annualized cost of diabetes treatment from baseline. 12 months
Other Change of the total costs of hyperlipidemia treatment Change of annualized cost of hyperlipidemia treatment from baseline. 12 months
Other Change of the medicine costs of hyperlipidemia treatment Change of annualized cost of hyperlipidemia treatment from baseline. 12 months
Other Medication compliance Change of the score of Morisky Medication Adherence Scale(MMAS-8) from baseline. 12 months
Other Health self assessment Change of the score of EuroQol five dimensions questionnaire from baseline. 12 months
Primary change of systolic pressure Change of systolic blood pressure from baseline 3 months
Primary change of diastolic pressure Change of diastolic blood pressure from baseline 3 months
Primary change of glycosylated hemoglobin Change of glycosylated hemoglobin from baseline 3 months
Primary change of fasting blood glucose Change of fasting blood glucose from baseline 3 months
Primary change of total cholesterol Change of total cholesterol from baseline 3 months
Primary change of low density lipoprotein cholesterol Change of low density lipoprotein cholesterol from baseline 3 months
Primary change of triglyceride Change of triglyceride from baseline 3 months
Secondary Compliance rate of blood pressure Change of the compliance rate of blood pressure from baseline 12 months
Secondary Compliance rate of glycosylated hemoglobin Change of the compliance rate of glycosylated hemoglobin from baseline 12 months
Secondary Compliance rate of low density lipoprotein cholesterol Change of the compliance rate of low density lipoprotein cholesterol from baseline 12 months
See also
  Status Clinical Trial Phase
Completed NCT03793985 - Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 Phase 1
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT04701775 - Effect of Different Probiotic Strains in Hypercholesterolemic Patients N/A
Completed NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 Phase 1
Completed NCT03534661 - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release Phase 2/Phase 3
Completed NCT03422666 - Plasma Lipoprotein Response to Glucagon-like Peptide-2 Phase 2/Phase 3
Completed NCT00536796 - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Recruiting NCT04560296 - Community-based E-Health Program for Older Adults Living With Chronic Diseases N/A
Terminated NCT04073134 - The CHORAL Flow Study Phase 4
Recruiting NCT05103254 - Bempedoic Acid Pregnancy Surveillance Program
Not yet recruiting NCT05015348 - Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients With Hyperlipidemia N/A
Active, not recruiting NCT05082350 - Nutritional Intervention With Black Garlic N/A
Not yet recruiting NCT04398771 - To Evaluate Safety and Effectiveness of RovatitanTab.
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Recruiting NCT06257641 - Impact of the Mediterranean Diet on Patients With Psoriasis N/A
Completed NCT03690778 - The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. Phase 1
Completed NCT04354987 - Compare the Pharmacokinetics and Safety of CKD-391 Phase 1